Tempus Algorithmic Test, PurISTSM Granted American Medical Association PLA Code
Tempus Algorithmic Test, PurISTSM Granted American Medical Association PLA Code
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced that the company's PurISTSM algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurISTSM PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory developed test (LDT), transcriptomic (RNA) data, representing a meaningful step towards reimbursement for AI-enabled algorithms.
人工智能與精準醫療領域的領導者Tempus AI, Inc. (NASDAQ: TEM)宣佈，該公司的PurISTSm算法測試已經獲得了美國醫學協會(AMA)的專有實驗室分析(PLA)代碼。新代碼將於2024年10月1日生效。PurISTSm PLA代碼是第一個描述先前測序、實驗室開發測試(LDT)、轉錄組(RNA)數據的僅算法分析的通用過程術語(CPT)代碼，代表着AI啓用算法的報銷向前邁出了重要的一步。
譯文內容由第三人軟體翻譯。